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S U M M A R Y
Background: Clinical ﬁndings suggest that the use of rectal culture-guided antibiotic prophylaxis reduces
the infection rate following transrectal ultrasound-guided prostate biopsy (TRUSBx).
Methods: A decision-analytic model was designed to compare the outcomes of TRUSBx performed with
(rectal culture-guided group) and without (standard ciproﬂoxacin prophylaxis) rectal swab culture-
guided antimicrobial prophylaxis in Hong Kong. The post-biopsy infection rate, infection-related costs,
quality-adjusted life years (QALYs) lost for infection, and incremental cost per QALY saved (ICER) were
assessed. Model inputs were retrieved from local epidemiology data and the medical literature. A
sensitivity analysis was performed to test the robustness of the model results.
Results: Base-case analysis showed that the infection rate in the culture-guided group was reduced from
2.42% to 0.23% and saved 0.0002 QALYs, with a lower cost (USD 31.4 versus USD 55.6) (USD 1 = HKD 7.8).
The number needed to screen to prevent an infection episode was 45.7. The hospital days avoided per
100 patients using culture-guided prophylaxis was 7.08 days. The relative effectiveness of culture-
guided antimicrobial prophylaxis versus standard prophylaxis in carriers and non-carriers of FQ-
resistant rectal ﬂora were identiﬁed as potential inﬂuencing factors. In 10 000 Monte Carlo simulations,
ICERs of the culture-guided group were below the willingness-to-pay threshold 99.12% of the time.
Conclusions: Using rectal culture-guided antimicrobial prophylaxis for men undergoing TRUSBx appears
to be a cost-saving strategy to avert post-biopsy infection and QALY loss in Hong Kong.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Despite the lower incidence of prostate cancer in Asian regions
than in Western nations, the Hong Kong Cancer Registry has
reported prostate cancer to be the third most common cancer in
men.1,2 Transrectal ultrasound-guided prostate biopsy (TRUSBx) is
a commonly performed procedure for the diagnosis of prostate
cancer, and infection (including urinary tract infection, prostatitis,
and sepsis) is a well-established complication of this procedure.
The rate of infection post-TRUSBx ranges from 0.5% to 6.6%, with
hospitalization rates between 0.5% and 4.8%.3
Fluoroquinolones (FQs) are frequently used for periprocedure
antimicrobial prophylaxis,4 yet the emerging prevalence of FQ-
resistant bacteria in faecal carriage of patients undergoing TRUSBx
has increased the risk of post-biopsy infection.5 Pre-biopsy rectal* Corresponding author. Tel.: +852-3943-6830; fax: +852-2603-5295.
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1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).swab culture is therefore suggested to identify the resistance of the
rectal ﬂora prior to selecting antimicrobial prophylaxis. The ﬁndings
of clinical trials strongly suggest that antimicrobial prophylaxis be
directed by rectal culture to reduce the odds of infection, with the
possibility of eliminating post-biopsy infection.6,7
With the initiatives of the Department of Health to enhance
public awareness of prostate cancer screening, the number of
males undergoing TRUSBx is anticipated to increase in Hong Kong.8
A recent study reported a high prevalence of FQ-resistant rectal
ﬂora (40.4%) in Hong Kong males undergoing TRUSBx, suggesting
that a targeted approach to antimicrobial prophylaxis using rectal
culture is warranted.9 A cost-effectiveness analysis is essential to
facilitate the decision-making process with regard to implement-
ing pre-TRUSBx rectal culture swab to guide the selection of
prophylactic agent. The objective of this study was to examine the
potential costs, post-biopsy infection rate, and health-related
quality of life of men undergoing TRUSBx with or without
periprocedure rectal swab culture, from the societal perspective
of Hong Kong.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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2.1. Model design
A decision-analytic model (Figure 1) was designed to compare
the economic and clinical outcomes of TRUSBx performed with
(rectal culture-guided group) and without (standard group) rectal
swab culture-guided antimicrobial prophylaxis. The outcomes
simulated in the present model included the post-biopsy infection
rate, infection-related direct medical cost and indirect cost, and
quality-adjusted life years (QALYs) lost for post-biopsy infection. A
hypothetical cohort of male subjects aged 55 years and above
(newly diagnosed cases of prostate cancer in Hong Kong have
mainly fallen into this age group10) undergoing TRUSBx were
included in this model. Exclusion criteria included allergy to FQ.
Rectal swabs would be collected for subjects in the culture-
guided group within 1 month prior to TRUSBx.6,7 The choice of
culture-speciﬁc regimen included sulfamethoxazole–trimetho-
prim, cefuroxime, or cefazolin monotherapy and the combination
of ciproﬂoxacin and gentamicin.6,7,11,12 Subjects in the standard
group would receive oral ciproﬂoxacin before TRUSBx.5,6,13–15 A
post-biopsy infection might occur in any patient in both study
arms; those who were infected might be managed in the
outpatient setting or be hospitalized. Post-biopsy infections were
deﬁned clinically, including urinary tract infection and blood-
stream infection.6,7 No mortality as a result of post-TRUSBx
infectious complications was reported in the local epidemiology
study,9 and the present model therefore assumed no post-biopsy
infection-related deaths.
2.2. Clinical inputs
A literature search of MEDLINE for the period 2000 to 2015 was
performed using the following key terms: ‘‘prostate biopsy’’,
‘‘ﬂuoroquinolone resistance’’, ‘‘rectal ﬂora’’, ‘‘antimicrobial pro-
phylaxis’’, ‘‘urinary tract infection’’, and ‘‘bacteremia’’. The selec-
tion criteria for the clinical trials were: (1) report written in the
English language; (2) prevalence of FQ-resistant rectal ﬂora was
reported, and/or (3) the post-biopsy infection rate was reported.
All articles retrieved by this process were screened for relevance to
the model. For a variable that was reported in multiple studies, the
weighted average was used to estimate the base-case value.
The clinical inputs are shown in Table 1. The base-case values of
the following clinical inputs were estimated from an epidemio-
logical study performed in Hong Kong Chinese men undergoing
TRUSBx:9 prevalence of FQ-resistant rectal ﬂora and post-biopsy
infection rates in carriers and non-carriers of FQ-resistant rectal
ﬂora in the standard group. The prevalence of FQ-resistant rectal
ﬂora (40.4%) reported in Hong Kong was found to be much higher
than those reported in other regions (10.8–19.6%).11,16–18 The
variation in prevalence of FQ resistance was therefore examinedFigure 1. Simpliﬁed decision-analytic model (TRUSBx, transrectal ultrover a range of 10.8–40.4%. The base-case values of relative
effectiveness of culture-targeted (versus standard) prophylaxis in
carriers (100%) and non-carriers (79%) of FQ-resistant rectal ﬂora
were estimated from a clinical trial comparing the post-biopsy
infection rate before and after the implementation of pre-
procedure rectal culture.7 A broad range (34–100%), with the
lower limit value (34%) reported in a case–control study,6 was
examined in the sensitivity analysis for these two variables. The
post-biopsy infection rate with culture-guided prophylaxis was
calculated using the following equation: infection rate with
standard ciproﬂoxacin prophylaxis  (1  relative effectiveness
of culture-guided prophylaxis).
The hospitalization rate of post-biopsy infection and length of
hospital stay were retrieved from outcome studies on post-biopsy
infectious complications of TRUSBx.13–15,19 For infected patients
who were managed exclusively in the outpatient setting, the
number of outpatient visits was assumed to be 2 (range 1–3),
including the ﬁrst visit for symptom onset and diagnosis and the
second visit for follow-up.
2.3. Cost inputs
The cost analysis of the present study was performed from the
societal perspective of Hong Kong and included the direct medical
cost (costs of rectal swab culture, standard and culture-guided
prophylactic regimens, and inpatient and outpatient care for post-
biopsy infection) and the indirect cost (loss of productivity during
post-biopsy infection).
The standard prophylactic regimen for TRUSBx in Hong Kong
was single-dose ciproﬂoxacin 500 mg taken perioperatively,9
and the empirical ciproﬂoxacin regimen varied from a single
dose to 6 doses (3 days).5–7,13–15 Culture-guided regimens
included monotherapy of sulfamethoxazole–trimethoprim,
cefuroxime, or cefazolin,7,17 and the combination of ciproﬂoxa-
cin and gentamicin.6,12 The costs of antibiotic prophylaxis were
calculated from the unit cost of antibiotic(s) and the quantity
taken.
The cost of infection for patients who were managed
exclusively in the outpatient setting was estimated from the
number of outpatient visits and cost per outpatient visit. The cost
of infection for patients who were hospitalized included both
inpatient and outpatient care. The cost of inpatient care was
calculated from the length of stay and daily cost of hospitalization
on the general medical ward. The model inputs for cost per
outpatient visit and daily cost of the general medical ward were
estimated from charges to non-residents of the Hospital Authori-
ty.20 The Hospital Authority is the largest public healthcare
provider for Hong Kong residents. It is non-proﬁt making and is
subsidized by the government, and the charges to non-residents
were therefore assumed to represent solely the cost of the
healthcare services without proﬁt.asound-guided prostate biopsy; FQR, ﬂuoroquinolone resistance).
Table 1
Model inputs
Base-case value Range for sensitivity analysis Reference
Clinical inputs
Prevalence of FQ-resistant rectal ﬂora 40.4% 10.8–40.4% 9, 11, 16–18
Rate of post-biopsy infection in standard prophylaxis group 7, 9
Carriers of FQ-resistant rectal ﬂora 3.33% 3.33–42.9%
Non-carriers of FQ-resistant rectal ﬂora 1.81% 1.81–2.70%
Relative effectiveness of rectal culture-targeted (versus standard) prophylaxis in: 6, 7
Carriers of FQ-resistant rectal ﬂora 100% 34–100%
Non-carriers of FQ-resistant rectal ﬂora 79.3% 34–100%
Rate of hospitalization for post-biopsy infection 64.6% 51.4–77.5% 13–15
Length of hospital stay for post-biopsy infection 5 3–7 19
Total length of antibiotic treatment for post-biopsy infection 21 14–28 19
Number of clinic visits for outpatient treatment of post-biopsy infection 2 1–3 Assumption
Utility inputs
Disutility of post-biopsy infection managed in the outpatient setting 0.14 0.168 to 0.112 22
Increment factor of disutility of post-biopsy infection in the hospital versus outpatient setting 2 1.5–3 Assumption
Cost inputs (USD)a
Rectal swab 25 18–30 Local
Cost of standard antimicrobial prophylaxisb 0.72 0.06–0.72 Local
Cost of culture-guided antimicrobial prophylaxisc 1.15 0.4–6.0 Local
Cost of outpatient visit for post-biopsy infection (per visit) 50 49–127 20
Cost of hospitalization for post-biopsy infection (per day) 600 480–720 20
Average salary of population aged 55 years or older (per day) 50 40–60 21
FQ, ﬂuoroquinolone; TRUSBx, transrectal ultrasound-guided prostate biopsy.
a USD 1 = HKD 7.8.
b The standard prophylactic regimen for TRUSBx in Hong Kong was single-dose ciproﬂoxacin 500 mg (base-case) and varied from a single dose to 6 doses (3 days).
c Culture-guided regimens included monotherapy with sulfamethoxazole–trimethoprim, cefuroxime, or cefazolin, and the combination of ciproﬂoxacin and gentamicin.
Table 2
Base-case analysis of expected costs, post-biopsy infection rate, and QALYs lost per
subject undergoing transrectal ultrasound-guided prostate biopsya
Culture-guided
prophylaxis group
Standard
prophylaxis
group
Total cost per patient (USD) $31.4 $55.6
Direct cost (USD) $30.8 $49.3
Indirect cost (USD) $0.6 $6.3
Post-biopsy infection rate
per 100 patients
0.23 2.42
Hospital days per 100 patients 0.74 7.82
QALY loss per patient 0.00002 0.00023
QALY, quality-adjusted life-year.
a USD 1 = HKD 7.8.
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was estimated from the median daily income (non-sex-speciﬁc) of
the Hong Kong population aged 55 years and above21 and the
length of hospitalization (for hospitalized cases only) and the
number of days attending the outpatient clinic (for all infected
patients).
2.4. Utility inputs
The loss of QALYs associated with post-biopsy infection was
examined. An outcome study of Chinese outpatients with
prostatitis reported a disutility of 0.14 compared to the utility
of the general population.22 The disutility of post-biopsy infection
managed in the hospital setting was assumed to be 2-fold (range
1–3-fold) the disutility of outpatient care. The QALY loss of patients
who received only outpatient care for infection was estimated
from the disutility of outpatient care and the length of antimicro-
bial treatment. The duration of the antimicrobial treatment course
was retrieved from an epidemiological study on prostatitis.18 The
QALY loss for hospitalized patients was estimated from the
disutility of hospitalization and length of hospital stay and from
the disutility of outpatient care and remaining duration of
antimicrobial therapy (remaining days of treatment = length of
treatment  length of hospital stay).
2.5. Cost-effective analysis and sensitivity analysis
The culture-guided group would dominate the standard group
if it cost less and resulted in QALYs saved. If the culture-guided
group cost more to save QALYs, the incremental cost per QALY
saved (ICER) was calculated using the following equation:
(Costculture-guided  Coststandard)/(QALY lossstandard  QALY losscul-
ture-guided). As recommended by the World Health Organization
(WHO), an ICER less than 1 GDP per capita was considered as
highly cost-effective.23 The GDP per capita of Hong Kong in
2014 was USD 39 758 and the scenario of an ICER less than USD
39 758 was considered as the preferred option.24
The sensitivity analysis was performed using TreeAge Pro 2009
(TreeAge Software, Inc., Williamstown, MA, USA) and MicrosoftExcel 2010 (Microsoft Corporation, Redmond, WA, USA) to examine
the robustness of the model results. All of the parameters were
examined over the upper and lower limits of the variables, if
available. Otherwise, a range of variation of 20% of the base-case
value was used. A one-way sensitivity analysis on all model inputs was
performed to screen for potential inﬂuencing factors. To evaluate the
impact of uncertainty in all variables simultaneously, a probabilistic
sensitivity analysis was performed using Monte Carlo simulation. The
total cost and QALYs of each study arm were recalculated 10 000 times
by randomly drawing each of the model inputs from a triangular
probability distribution to determine the percentage of time in which
each strategy would be the preferred option.
3. Results
3.1. Base-case analysis
In the base-case analysis (Table 2), the culture-guided group
showed a reduction in the post-biopsy infection rate of 90.5% (from
2.42% to 0.23%); 0.0002 QALYs per patient were saved. The number
needed to screen to prevent an infection was 45.7. In comparison
with the standard group, the culture-guided group reduced the
total cost per patient undergoing biopsy by 43.5% (USD 31.4 versus
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reduced the direct cost by 37.5% (USD 30.8 versus USD 49.3) from
the healthcare payer’s perspective. The hospital days avoided per
100 patients by culture-guided prophylaxis was 7.08 days. The
culture-guided group showed a reduced infection rate with cost
saving and lower QALY loss, and therefore dominated the standard
group in the base-case scenario.
3.2. Sensitivity analysis
The one-way sensitivity analysis found the base-case results to
be robust throughout variation of all model inputs. The relative
effectiveness of culture-guided antimicrobial prophylaxis versus
standard prophylaxis in carriers and non-carriers of FQ-resistant
rectal ﬂora were identiﬁed as potential inﬂuencing factors. TheseFigure 2. Three-way sensitivity analysis of relative effectiveness of culture-guided
versus standard prophylaxis in carriers and in non-carriers of ﬂuoroquinolone (FQ)-
resistant rectal ﬂora on increment cost per QALY saved (ICER) at various prevalence
levels of FQ-resistant rectal ﬂora: (a) 10%, (b) 25%, (c) 40%. The threshold line divides
the grey zone and white zone. Combinations of variables on the threshold line had
the same cost-effectiveness for both study arms. Grey zone: combinations of
variables leading to ICERs in the culture-guided group of less than the willingness-
to-pay threshold (USD 39 758) (preferred option = culture-guided group). White
zone: combinations of variables leading to ICERs in the culture-guided group
greater than the willingness-to-pay threshold (USD 39 758) (preferred
option = standard group).two inputs were examined further over an extended range (0.1–
100%) at three prevalence levels of FQ-resistant rectal ﬂora (10%,
25%, and 40%) by three-way sensitivity analysis (Figure 2). The
number of variable combinations preferring the culture-guided
group (as indicated by the size of the grey area in Figure 2)
increased from a low level prevalence of FQ resistance to a high
level of FQ resistance. At a low prevalence of FQ resistance (10% and
25%), the relative effectiveness of culture-guided prophylaxis in
non-carriers of FQ-resistant rectal ﬂoral was the prominent
inﬂuencing factor, and thresholds of >40% (at 10% of FQ-
resistance) and >10% (at 25% of FQ-resistance) were identiﬁed
for the culture-guided group to be cost-effective. At a high
prevalence of FQ resistance (40%), a threshold value of 72.6% for
relative effectiveness of culture-guided prophylaxis in carriers was
identiﬁed when the relative effectiveness in non-carriers was at
the lower limit (0.1%). To examine the impact of high antimicrobial
regimen cost in the present model analysis, the cost range of
culture-speciﬁc antimicrobial prophylaxis was extended from USD
0.4–6 to USD 0.4–50 in a one-way sensitivity analysis; the culture-
guided group remained cost-saving if the prophylactic regimen
cost less than USD 25.6.
The probabilistic sensitivity analysis was performed by
10 000 Monte Carlo simulations. The culture-guided group was
signiﬁcantly less costly and more effective than the standard
group, with a mean cost saving of USD 17.9 (95% conﬁdence
interval (CI) 17.7–18.1; p < 0.001) and 0.000180 QALY saved (95%
CI 0.000179–0.000181; p < 0.001). A scatter plot showing the
incremental cost versus QALY saved by culture-guided group is
given in Figure 3. The culture-guided group reduced the cost and
saved QALYs in 96.03% of the simulations, and it cost more to save
QALYs in 3.97% of the simulations. The ICERs per QALY saved by the
culture-guided group were below the willingness-to-pay thresh-
old in 99.12% of the simulations. The acceptability of culture-
guided prophylaxis as the preferred option changed from 96.0% to
99.5% when the willingness-to-pay threshold increased from USD
0 to USD 50 000, respectively.
4. Discussion
The base-case results of the present study found rectal culture-
guided prophylaxis to be cost-saving and to gain QALYs when
compared with standard prophylaxis in patients undergoing
TRUSBx from the societal perspective of Hong Kong. Culture-
guided prophylaxis reduced the total cost (per man undergoing
TRUSBx) by over 40% (from USD 55.6 to USD 31.4), including the
direct medical costs for the prevention and treatment of infection-70
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Figure 3. Scatter plot of incremental cost versus incremental QALYs saved by
culture-guided prophylaxis versus standard prophylaxis.
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productivity for post-biopsy infection (indirect cost) by over 90%
(from USD 6.3 to USD 0.6). The infection rate was reduced by over
90% (from 2.42% to 0.23%). The robustness of the base-case analysis
ﬁndings was demonstrated in both the one-way sensitivity
analysis (no threshold value for all model inputs) and the
probabilistic sensitivity analysis (culture-guided group was the
preferred option in over 99% of 10 000 Monte Carlo simulations).
The one-way sensitivity analysis found two variables (relative
effectiveness of culture-guided prophylaxis versus standard
prophylaxis in FQ-resistant ﬂora carriers and non-carriers) to
inﬂuence the ICER of the culture-guided group, despite no
threshold value being identiﬁed. The interactions of varying these
two model inputs over three prevalence levels of FQ resistance in a
three-way sensitivity analysis showed that the relative effective-
ness of culture-guided prophylaxis in carriers was most inﬂuential
in scenarios with a high prevalence of FQ-resistant rectal ﬂora,
when compared to those with a low prevalence.
In a prospective cohort study (n = 457) conducted in the USA,
Taylor et al. reported that there was no infectious complication in
112 men who received culture-guided antimicrobial prophylaxis,
whereas infectious complications occurred in nine of 345 (2.6%)
men on standard prophylaxis. The cost analysis of this cohort study
demonstrated a cost-saving of USD 4499 per post-biopsy infection
averted with a number needed to screen of 38.11 The present
analysis found culture-guided prophylaxis to be cost-saving per
infection avoided (USD 1,105) and the number needed to screen to
prevent one infectious complication was found to be 45.7. These
results are similar to the cost-effectiveness ﬁndings reported by
Taylor et al., despite higher cost-savings demonstrated in the US
study. The difference was mainly due to the low healthcare service
unit cost and drug costs in Hong Kong (Table 1) compared to the US
Medicare reimbursement rate for infection.11 For every case of
infection averted, a relatively lower direct cost of treatment was
saved in Hong Kong compared to the USA because of the lower cost
of care in Hong Kong.
A cost-effectiveness analysis comparing standard versus
intensive antibiotic prophylaxis for TRUSBx reported by Adibi
et al. using decision tree analysis from the perspective of US
healthcare providers, showed standard prophylaxis (drug cost USD
1) to be less costly than an intensive antibiotic regimen (drug cost
USD 33), but this resulted in a higher post-biopsy infection rate.25
The present sensitivity analysis further identiﬁed the threshold of
culture-targeted antimicrobial drug cost to be US 25.6 or less for
pre-biopsy rectal culture screening to remain cost-saving. Com-
pared to empirical broad-spectrum antibiotic prophylaxis, culture-
guided prophylaxis could reduce the drug costs without
compromising the effectiveness in infection prevention.
This is the ﬁrst cost-effectiveness analysis conducted from the
societal perspective of Hong Kong to include direct medical costs and
indirect costs, as well as the post-biopsy infection rate and QALY loss
of patients undergoing TRUSBx with and without pre-biopsy rectal
swab culture. The present study identiﬁed inﬂuencing factors and
corresponding threshold values (high versus low prevalence of FQ-
resistant rectal ﬂora, relative effectiveness of culture-guided
prophylaxis in carriers and non-carriers of FQ-resistant rectal ﬂora),
which may serve as reference values to assist clinicians and
administrators in deciding the prophylaxis protocol for TRUSBx. The
base-case results supported rectal culture-guided prophylaxis in a
city with a high prevalence of FQ resistance (40%), and the ﬁndings
were further shown to be robust and generalizable to low prevalence
(10%) regions in the sensitivity analysis. The present model
framework, including key clinical and cost parameters, allowed
the incorporation of different antimicrobial regimens using agent-
speciﬁc costs, the region- or institution-speciﬁc prevalence of FQ-
resistance, and agent-speciﬁc effectiveness for the prevention ofpost-biopsy infection to better reﬂect the costs and clinical
outcomes of different practice settings.
A high prevalence of FQ-resistant rectal ﬂora has been reported
in Chinese men undergoing TRUSBx in Hong Kong. Despite the
post-biopsy infection rate using standard prophylaxis with oral
ciproﬂoxacin remaining low (2.4%) in Hong Kong,9 ﬁndings in
recent cohort trials have demonstrated the possibility of eliminat-
ing post-biopsy infection with culture-guided prophylaxis.7,11,18
The results of the present study further support the economic and
clinical beneﬁts of a rectal culture-guided prophylaxis protocol for
TRUSBx.
The present study was limited by the sources of clinical
effectiveness of culture-guided prophylaxis, mostly estimated
from cohort studies. The clinical inputs were therefore examined
over a wide range in the sensitivity analysis to examine their
inﬂuence on the robustness of model results. This model simpliﬁed
the outcomes of post-biopsy infection and did not differentiate the
severity of infectious complications between patients infected
with drug-resistant versus susceptible pathogens. Thus the clinical
beneﬁts of culture-guided prophylaxis might be underestimated.
The estimation of productivity loss did not include the indirect cost
of caregivers and might have undermined the cost-savings of
culture-guided prophylaxis.
In conclusion, rectal culture-guided antimicrobial prophylaxis
for men undergoing TRUSBx appears to be a cost-saving strategy
compared to standard ciproﬂoxacin prophylaxis to avert post-
biopsy infection and infection-associated QALY loss, from the
societal perspective of Hong Kong.
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